Advance Search

Promyelocytic blast crisis of chronic myeloid leukemia after one year of Imatinib treatment

Nawsherwan Sadiq
Ministry of Health, Kurdistan Region, Erbil, Iraq
Mohammed Dhahir Ali
Department of Pharmacology, College of Medicine, Hawler Medical University, Erbil, Iraq.
Keywords:
Copyright and Licensing:

Copyright (c) 2013 Nawsherwan Sadiq, Mohammed Dhahir Ali (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Share:
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

A 60 year-old man in the chronic phase of chronic myeloid leukemia (CML-CP) was treated with imatinib mesylate for 1 year. After one year of the initial diagnosis of CML chronic phase, the patient progressed to a promyelocytic blast crisis, karyotyping showed 46,XY,t(9;22)(q34;q11.2), t(15;17)(q22;q21) in all cells examined. The patient was diagnosed with promyelocytic blast crisis of CML. With administration of all-trans retinoic acid (ATRA) and high-dose imatinib mesylate (800 mg/day), the patient has died of disseminated intravascular coagulation within 2 weeks. As karyotyping showed 46,XY,t(9;22)(q34;q11.2), t(15;17)(q22;q21) in all cells examined, this is suggesting that the clonal evolution of PML/RARa translocation occurred early in the CML-CP.

PDF
PDF

Metrics

Metrics Loading ...

References

  1. Sawyers C. L. Chronic Myeloid Leukemia. Review Article. New England Journal of Medicine 1999; 340(17):1330-1340.
  2. Martinelli, G.; Iacobucci, I. Imatinib resistance: the role of BCRABL dependent and independent mechanism in the loss of response to tyrosine kinase inhibitors. In: Education program of the 13th congress of the EHA, 2008, p. 8-12.
  3. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103:4010-4022.
  4. Fuscaldo KE, Brodsky I, Kahn SB, Conroy JF, Marfurt K. Myeloproliferative disorders: III. CML. Further studies on the role of cytogenetics in diagnosis, prognosis and management. Haematologica 1981; 66: 461-488.
  5. Abe R, Shichishima T, Kawaguchi M, Uchida T, Kariyone S. Promyelocytic crisis of chronic myelogenous leukemia without t(15;17). Cancer Genet Cytogenet 1986;21:175-179.
  6. Emilia G, Sacchi S, Selleri L, Zucchini P, Artusi T, Torelli U. Promyelocytic crisis of chronic myeloid leukaemia. Br J Haematol 1987;66:276-277.
  7. Hogge DE, Misawa S, Schiffer CA, Testa JR. Promyelocytic blast crisis in chronic granulocytic Leukemia with 15;17 translocation. Leuk Res 1984;8:1019-1023.
  8. Louwagie AC, Mecucci C, Criel A, Van Hoof A, Van den Berghe H. Variant translocation t(15q;17q) accompanying a promyelocytic accelerated phase of Ph-positive chronic myeloid leukemia. Cancer Genet Cyto-genet 1987;28:349-352.
  9. Matsue K, Yamada K, Takeuchi M, Tabayashi T. Rapid improvement of disseminated intravascular coagulation by donor leukocyte infusions in a patient with promyelo-cytic crisis of chronic myelogenous leukemia after reduced-intensity stem cell transplantation from an HLA 2-antigen-mismatched mother. Int J Hematol 2003;77:408-411.
  10. Mijovic A, Rolovic Z, Novak A, Biljanovic-Paunovic L, Tomin D. Chronic myeloid leukemia associated with pure red cell aplasia and terminating in promyelocytic transformation. Am J Hematol 1989;31:128-130.
  11. Misawa S, Lee E, Schiffer CA, Liu Z, Testa JR. Association of the translocation (15;17) with malignant proliferation of promyelocytes in acute kjxleukemia and chronic myelogenous leukemia at blastic crisis. Blood 1986;67:270-274.
  12. Oren H, Duzovali O, Yuksel E, Sakizli M, Irken G. Development of acute promyelocytic leukemia with isochromosome 17q after BCR/ABL positive chronic myeloid leukemia. Cancer Genet Cytogenet 1999;109: 141-143.
  13. Rosenthal NS, Knapp D, Farhi DC. Promyelocytic blast crisis of chronic myelogenous leukemia. A rare subtype associated with disseminated intravascular coagulation. Am J Clin Pathol 1995;103:185-188.
  14. Scolnik MP, Palacios MF, Acevedo SH, Castuma MV, Larripa IB, Palumbo A, et al. Promyelocytic blast crisis of chronic myelogenous leukaemia with translocations (9;22) and (15;17). Leuk Lymphoma 1998;31:231-236.
  15. van der Merwe T, Bernstein R, Derman D, Stanley A, Dukes I, Murray J, et al. Acute promyelocytic transformation of chronic myeloid leukaemia with an isochromosome 17q. Br J Haematol 1986;64:751-756.
  16. Wiernik PH, Dutcher JP, Paietta E, Hittelman WN, Vyas R, Strack M, et al. Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all trans-retinoic acid. Leukemia 1991;5:504-509.
  17. Gozzetti A, Bocchia M, Calabrese S, Pirrotta MT, Crupi R, Raspadori D, et al. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment. Acta Haematol 2007;117:236-237.
  18. Chung, H. J, Chi, H. S, Cho, Y. U, Park, C. J, Seo, E. J, Kim, K. H et al. Case Report: Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment. Annals of Clinical & Laboratory Science 2008; 38: 283-286.
How to Cite
Sadiq, N., & Ali, M. D. (2013). Promyelocytic blast crisis of chronic myeloid leukemia after one year of Imatinib treatment. Zanco Journal of Medical Sciences (Zanco J Med Sci), 17(3), 590–593. https://doi.org/10.15218/zjms.2013.0053

Send mail to Author

Send Cancel